Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China - Poll - MDSpire

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

  • By

  • Zhangyuting He

  • Huiying Zhu

  • Chong Wei

  • Danqing Zhao

  • Jing Ruan

  • Wei Zhang

  • Daobin Zhou

  • Yan Zhang

  • July 6, 2026

  • 0 min

Share

Original Source(s)

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

  • by Zhangyuting He, Huiying Zhu, Chong Wei, Danqing Zhao, Jing Ruan, Wei Zhang, Daobin Zhou, Yan Zhang

  • July 6, 2026

Related Content

Effects of different art therapies on the psychological well-being and quality of life in cancer survivors: a systematic review and network meta-analysis

Locus-specific HERV expression identifies an aggressive, NK-depleted, checkpoint-refractory acral melanoma phenotype

Artificial intelligence in three-dimensional total-body photography for skin cancer surveillance